Trading Signals: LGND Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 27, 2023)(Ligand Pharmaceuticals Inc)
| LGND latest price $254.3900 (-1.59%) ($248.7200 - $257.0900) on Wed. Sep. 5, 2018. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.11% (three month average) | RSI | 57 | Latest Price | $254.3900(-1.59%) | Stocks Behave Similarly | Similar Stock List | Weekly Trend | LGND advances 2.7% a week on average for past two weeks. | Market Behavior | Rotation from growth to value for large cap. Growth stock sell-off for small cap. | Correlated ETFs | Broad market will support LGND advance at 0% a week (0% probability) IBB(60%) IWO(57%) XBI(56%) IWC(54%) IWM(53%) | Factors Impacting LGND price | LGND will decline at least -1.055% in a week (0% probabilities). VXX(-16%) TLT(-16%) VIXM(-13%) UUP(-9%) GDXJ(-7%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.055% (StdDev 2.11%) | Hourly BBV | 0 () | Intraday Trend | -1% | | | |
|
5 Day Moving Average | $257.37(-1.16%) | 10 Day Moving Average | $254.89(-0.2%) | 20 Day Moving Average | $249.54(1.94%) | To recent high | -2% | To recent low | 37.5% | Market Cap | $4.088b | | | | Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA. |